cariprazine
Vraylar (cariprazine) is an atypical antipsychotic with a unique preference for dopamine D3 receptors. It is used for schizophrenia, manic or mixed episodes of bipolar I disorder, bipolar depression, and as add-on therapy for major depressive disorder. Rather than fully blocking dopamine signals, it partially stimulates D3 and D2 receptors, helping to stabilize overactive circuits.
This page is based on EMA and FDA prescribing information for cariprazine, cross-checked with DailyMed labeling and MedlinePlus; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
In schizophrenia and bipolar disorder, dopamine signaling can swing too high or too low in different brain circuits. Instead of slamming the door on dopamine, cariprazine acts like a dimmer switch — when dopamine is too high, it turns the signal down; when dopamine is too low, it gives a gentle boost. Its special preference for D3 receptors may also help with motivation and clear thinking.
In simple terms
Cariprazine is an atypical antipsychotic that works differently from most others in its class. Instead of fully blocking dopamine receptors, it is a partial agonist — meaning it can both stimulate and calm dopamine signaling depending on the brain's needs. It strongly prefers D3 receptors, found in brain areas handling motivation, reward, and clear thinking, over the more common D2 receptors. This D3 preference may help with negative symptoms of schizophrenia (like loss of motivation) and cognitive difficulties. Cariprazine also blocks serotonin 5-HT2B and 5-HT2A receptors, which helps stabilize mood and reduces certain movement side effects. Its active metabolites have very long half-lives, so the drug builds up gradually and stays in the system for weeks after stopping.
In depth
Cariprazine and its active metabolites desalkyl-cariprazine (DRC) and didesalkyl-cariprazine (DCRC) are partial agonists at dopamine D3 and D2 receptors, with approximately 10-fold higher affinity for D3 over D2. D3-preferring partial agonism is thought to modulate mesolimbic and mesocortical dopamine tone, potentially improving negative and cognitive symptoms of schizophrenia. Cariprazine also antagonizes serotonin 5-HT2B and 5-HT2A receptors (the latter contributing to antipsychotic and mood-stabilizing effects with lower extrapyramidal risk) and has moderate affinity for 5-HT1A receptors (partial agonism). The extremely long half-lives of DRC (~3 weeks) and DCRC (~1 week) result in a slow accumulation over several weeks and a prolonged tail after discontinuation. Cariprazine has low affinity for histaminergic, muscarinic, and adrenergic receptors, which explains its relatively low sedation and metabolic burden.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How cariprazine, a D3-preferring partial agonist, modulates dopamine and serotonin
- Instead of slamming the door on dopamine, cariprazine acts like a dimmer switch — when dopamine is too high, it turns the signal down; when dopamine is too low, it gives a gentle boost.
- Cariprazine and its active metabolites desalkyl-cariprazine (DRC) and didesalkyl-cariprazine (DCRC) are partial agonists at dopamine D3 and D2 receptors, with approximately 10-fold higher affinity for D3 over D2.
- Cariprazine also antagonizes serotonin 5-HT2B and 5-HT2A receptors (the latter contributing to antipsychotic and mood-stabilizing effects with lower extrapyramidal risk) and has moderate affinity for 5-HT1A receptors (partial agonism).
- The extremely long half-lives of DRC (~3 weeks) and DCRC (~1 week) result in a slow accumulation over several weeks and a prolonged tail after discontinuation.
Target: Dopamine D3 and D2 receptors
D3 receptors are concentrated in brain areas involved in motivation, reward, and cognition; D2 receptors mediate classic antipsychotic effects. Cariprazine partially stimulates both, stabilizing dopamine signaling rather than fully blocking it.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in European Union
EMA- Treatment of schizophrenia in adult patients
Approved uses in United States
FDA- Treatment of schizophrenia in adult and pediatric patients 13 years of age and older
- Acute treatment of manic or mixed episodes associated with bipolar I disorder in adult and pediatric patients 10 years of age and older
- Treatment of depressive episodes associated with bipolar I disorder in adult patients
- Adjunctive therapy to antidepressants for major depressive disorder in adult patients
Approved uses in United States
DailyMed- Treatment of schizophrenia in adult and pediatric patients 13 years of age and older
- Acute treatment of manic or mixed episodes associated with bipolar I disorder
- Treatment of depressive episodes associated with bipolar I disorder
- Adjunctive therapy to antidepressants for major depressive disorder
Approved uses in United States
MedlinePlus- Treatment of schizophrenia, bipolar disorder, and major depressive disorder
Official sources
The statements on this page trace back to these records.
- Reagila (cariprazine) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- U.S. Food and Drug Administration: cariprazine (Vraylar) prescribing information
U.S. Food and Drug Administration
- DailyMed: cariprazine (Vraylar) labeling
DailyMed, U.S. National Library of Medicine
- MedlinePlus: cariprazine
MedlinePlus, U.S. National Library of Medicine
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.